Aghai, Fatemeh
Zimmermann, Sebastian
Kurlbaum, Max
Jung, Pius
Pelzer, Theo
Klinker, Hartwig
Isberner, Nora
Scherf-Clavel, Oliver http://orcid.org/0000-0002-1967-9231
Funding for this research was provided by:
Hector Stiftung II gGmbH (MED 1807)
Article History
Received: 7 August 2020
Revised: 2 October 2020
Accepted: 27 October 2020
First Online: 6 November 2020
Compliance with ethical standards
:
: The study was approved by the Ethics Commission of the University of Wuerzburg (ref199/18-am) and was conducted in accordance with the declaration of Helsinki.
: All patients gave written informed consent.
: All patients gave written informed consent.
: Oliver Scherf-Clavel reports endowed professorship grant (Horphag Research Ltd.). Oliver Scherf-Clavel, Nora Isberner, and Hartwig Klinker received funding for the project “Individualized cancer therapy with kinase inhibitors using drug monitoring – optimization by minimally invasive at-home sampling” (Hector Stiftung II gGmbH). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All authors declare the absence of all other possible conflicts of interest.